NANETS Regional NET Education: The Multidisciplinary Management of NET Disease

May 2022

7:30am – 4:00pm 

Earn up to 6.5 AMA PRA Category 1 Credits,™ Continuing Nursing Education (CNEG), and MOC accreditation


Chicago Marriott Downtown Magnificent Mile
540 Michigan Ave.
Chicago, IL 60611


Jointly Provided by the University of Chicago Medicine and the North American Neuroendocrine Tumor Society

Course Director

Xavier Keutgen, MD, University Chicago Medicine


Neuroendocrine tumors (NET) are considered to be a rare disease although the frequency of diagnosis has dramatically increased over the last ten years, including within the Chicagoland area. As this is a rare disease and since the diagnostic and therapeutic landscape has significantly changed over the past decades, clinicians can sometimes struggle to set up a multidisciplinary long-term care plan for their NET patients. During this symposium we will therefore review all aspects of specialized NET care and present unique tips and tricks on how to treat these complex patients. Moreover, we will have two keynote lectures from other NANETS members regarding the future of systemic NET therapy and familial syndromes associated with NETs.

Target Audience

This activity is designed for oncologists, gastroenterologists, pulmonologists, surgeons, radiologists, pathologists, primary care physicians, advanced practice nurses, nurses, physician assistants, pharmacists, fellows, students, and other allied health professionals involved with or interested in the treatment of patients with neuroendocrine tumors.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Review current concepts of neuroendocrine tumor pathology, molecular profile, classification, and grading
  • Discuss the various diagnostic processes and use of current and emerging diagnostic tools to determine neuroendocrine tumor type
  • Summarize the current safety and efficacy data of the various surgical, medical and loco-regional approaches in the management of neuroendocrine tumors
  • Recognize the clinical features associated with carcinoid syndrome
  • Apply a multidisciplinary approach to the management of patients with neuroendocrine tumors
  • Review clinical trial data and ongoing studies evaluating novel management strategies for the treatment of neuroendocrine tumors


7:30-8:00 am     Registration & Breakfast

8:00-8:10 am     Welcome and Opening Remarks

8:10-9:00 am     Overview of Neuroendocrine Tumors

  • Background, Epidemiology, et
  • Imaging for Diagnosis & follow etc (what is the role of GaDOTATATE in Dx and F/U?)
  • Endoscopic diagnosis etc
  • Path of NETs: General features, etc

9:00-10:00 am  Surgical Treatment of localized and metastatic NETs

  • Surgical principles in gastroduodenal and  small bowelNETs (including interop management with Octreotide)
  • Surgical principles in pancreatic NETs
  • Role of liver debulking surgery for GEP-NETs 
  • Panel: Q/A 

10:00-10:15 am   Break

10:15-10:45 am   Peptide receptor radionuclide therapy (PRRT)

  • European and American evidence
  • Panel: Q/A 

10:45-11:15 am    Medical Management of metastatic NETs

  • Octreotide Analogues
  • Targeted Therapy (Everolimus, Sunitinib)
  • Chemotherapy (include poorly differentiated NEC)
  • Panel: Q/A 

11:15-11:45 am    The future of NET treatment

  • 2nd Generation PRRT (antagonists and alpha particles)
  • Immunotherapy
  • Promising Clinical Trials
  • Panel: Q/A 

11:45-12:30 pm  Tumor Board (2-3 cases)

12:30-1:30 pm    Lunch

1:30-2:15 pm      Hereditary Syndromes and NETs

  • Pheochromocytomas/Paragangliomas
  • Hereditary Syndromes associated with PNETs (MEN1, VHL)
  • Panel: Q/A 

2:15-2:45 pm     Liver-directed therapy for NET

  • Bland- and chemoembolization
  • Radioembolization
  • Panel: Q/A 

2:45-3:15 pm    Hormonal Management of NETs

  • Hormonal syndromes etc
  • Symptom Control in NETs
  • Panel: Q/A 

3:15 – 3:45 pm   Closing Remarks, Feedback and Adjourn


This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint providership of CMEsolutions and North American Neuroendocrine Tumor Society. The CMEsolutions is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The CMEsolutions designates this live activity for a maximum of 6.5 AMA PRA Category 1 Credits.™  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This activity has been submitted to the Continuing Nursing Education Group, for approval to award nursing contact hours. The Continuing Nursing Education Group is accredited as an approver of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation. 

In-person registration is available onsite the day of the program and will be accommodated on a space-available basis

Registration fee:


$65 - MD, PharmD, Doctoral Level 
$35 - Allied Health
Complimentary - Student/Fellow/Resident


$95 - MD, PharmD, Doctoral Level 
$50 - Allied Health
Complimentary - Student/Fellow/Resident

Cancellation Policy:

A full refund will be made if registration is canceled, in writing, on or before May 10, 2020. On or after May 11, 2020, no refund will be made.

The University Chicago Medicine and the North American Neuroendocrine Tumor Society reserve the right to modify the activity content, faculty, and activities and reserve the right to cancel this activity if necessary. If the program is canceled, liability is limited to the registration fee.


Please contact us with any questions.